Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

This study has been completed.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Boston Children’s Hospital
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Maureen Okam, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01000155
First received: October 20, 2009
Last updated: November 25, 2015
Last verified: November 2015

October 20, 2009
November 25, 2015
October 2009
October 2014   (final data collection date for primary outcome measure)
Percent Fetal Hemoglobin (HbF%) Induction Success Rate [ Time Frame: HbF% was measured at baseline and weekly on treatment. Median duration of treatment was 3 months. ] [ Designated as safety issue: No ]
Success will be defined by comparing the maximum HbF% on study drug to the HbF% at baseline. An absolute increase in HbF% of 4% of more, or an increase to 100% or more of baseline in patients with HbF under 4% at baseline will be considered a success. HbF% induction success rate is calculated as the count of successes divided by the count of particpants in the analysis population.
  • To determine the efficacy of vorinostat when administered orally in inducing a 4% absolute increase or a 100% increase in fetal hemoglobin levels in subjects with severe sickle cell disease who have failed prior therapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To characterize the safety and tolerability of vorinostat in subjects with sickle cell disease. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01000155 on ClinicalTrials.gov Archive Site
Not Provided
  • To assess the effect of vorinostat on F-cell levels. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the changes is y-globin, B-globin and E-globin RNA levels during treatment with vorinostat. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To describe the dose-response characteristics of vorinostat in inducing fetal hemoglobin in sickle cell disease [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy
Sickle Cell Disease (SCD) is a hereditary anemia that causes the red blood cells to change their shape from a round and doughnut-like shape to a half-moon/crescent, or sickled shape. People who have SCD have a different type of hemoglobin (protein that carries oxygen). This different type of hemoglobin makes the red blood cells change into a crescent shape under certain conditions. Sickle-shaped cells are a problem because they often get stuck in the blood vessels blocking the flow of blood and can cause inflammation and injury to important areas of the body. All babies are born with hemoglobin called fetal hemoglobin (HbF). Soon after birth, HbF production slows down and another hemoglobin called adult hemoglobin (HbA) is made. Clinical studies have shown that increasing the amount of HbF in the blood may prevent sickling of the red blood cells. Vorinostat has been used in the treatment of cancers and in other research studies and information from those suggests that it may help treat SCD by increasing the amount of HbF in the blood. The purpose of this research study is to determine the effectiveness and safety of vorinostat when used to treat SCD.

OBJECTIVES:

Primary

  • To determine the efficacy of vorinostat (suberoylanilide hydroxamic acid, SAHA), when administered orally, in a pulsed fashion, once-a-day for 3 consecutive days every week, in inducing a 4% absolute increase or a 100% increase in fetal hemoglobin percent levels (HbF%) in subjects with severe sickle cell disease who have failed prior therapy.
  • To characterize the safety and tolerability.

Secondary

  • To assess the effect of vorinostat on F-cell levels.
  • To determine the changes in y-globin, B-globin and E-globin RNA levels during treatment with vorinostat.
  • To describe the dose-response characteristics of vorinostat in inducing fetal hemoglobin in sickle cell disease.

Exploratory

  • To determine the extent and duration of global histone acetylation with intermittent vorinostat dosing.
  • To correlate the status of polymorphisms near the BCL11A, c-myb, and HBB gene loci, all of which are associated with levels of fetal hemoglobin, to assess for an association of polymorphism status with therapeutic response to vorinostat.
  • To evaluate red blood cell rheology before and after treatment with vorinostat.

STATISTICAL DESIGN:

This was a single stage design to evaluate induction of HbF on treatment with target enrollment of 15 patients. A 25% success rate was considered evidence of activity in this patient population while 5% success rate deemed ineffective. If at least 3 patients achieved success, the treatment would be considered promising. With 15 eligible patients, the probability of observing this was 0.76 assuming a true rate of 25% and 0.04 assuming a true rate of 5%.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Sickle Cell Disease
  • Sickle Cell Anemia
Drug: vorinostat
Other Name: SAHA
Experimental: Vorinostat
Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
Intervention: Drug: vorinostat
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of sickle cell disease
  • Clinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease
  • Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea
  • 18 years of age or older
  • Hematologic laboratory values as outlined in the protocol
  • Non-hematologic laboratory values as outlined in the protocol
  • Must agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter
  • Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment
  • Women of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Subjects with hemoglobin SC or SB+ thalassemia
  • Subjects on chronic transfusion program
  • Subjects who have received RBC transfusions cannot have >15% adult hemoglobin
  • Known positive status for HIV, active hepatitis B or hepatitis C
  • Pregnant or breast feeding women
  • Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin
  • Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk
  • Subjects with unresolved infections
  • Severe or uncontrolled medical conditions that could compromise study participation
  • Subjects on fetal hemoglobin inducing agents
  • Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy
  • Known allergic reaction to a histone deacetylase inhibitor
  • Subjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment
  • Subjects who have received any HDAC inhibitors other than valproic acid
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01000155
09-237
Yes
Not Provided
Not Provided
Maureen Okam, MD, MPH, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Boston Children’s Hospital
  • Merck Sharp & Dohme Corp.
Principal Investigator: Maureen Okam, MD, MPH Brigham and Women's Hospital
Dana-Farber Cancer Institute
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP